HomeCompareAELIY vs ABBV

AELIY vs ABBV: Dividend Comparison 2026

AELIY yields 6.81% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AELIY wins by $37720.74M in total portfolio value
10 years
AELIY
AELIY
● Live price
6.81%
Share price
$8.22
Annual div
$0.56
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37720.85M
Annual income
$36,685,798,336.94
Full AELIY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AELIY vs ABBV

📍 AELIY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAELIYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AELIY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AELIY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AELIY
Annual income on $10K today (after 15% tax)
$578.75/yr
After 10yr DRIP, annual income (after tax)
$31,182,928,586.40/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AELIY beats the other by $31,182,907,530.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AELIY + ABBV for your $10,000?

AELIY: 50%ABBV: 50%
100% ABBV50/50100% AELIY
Portfolio after 10yr
$18860.47M
Annual income
$18,342,911,554.35/yr
Blended yield
97.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AELIY
No analyst data
Altman Z
0.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AELIY buys
0
ABBV buys
0
No recent congressional trades found for AELIY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAELIYABBV
Forward yield6.81%3.06%
Annual dividend / share$0.56$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$37720.85M$102.3K
Annual income after 10y$36,685,798,336.94$24,771.77
Total dividends collected$37649.63M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AELIY vs ABBV ($10,000, DRIP)

YearAELIY PortfolioAELIY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,062$1,361.78$11,550$430.00+$512.00AELIY
2$15,976$3,070.18$13,472$627.96+$2.5KAELIY
3$24,696$7,601.05$15,906$926.08+$8.8KAELIY
4$48,386$21,961.66$19,071$1,382.55+$29.3KAELIY
5$132,202$80,428.60$23,302$2,095.81+$108.9KAELIY
6$552,202$410,746.33$29,150$3,237.93+$523.1KAELIY
7$3,797,724$3,206,867.98$37,536$5,121.41+$3.76MAELIY
8$45,287,807$41,224,241.65$50,079$8,338.38+$45.24MAELIY
9$967,333,631$918,875,678.03$69,753$14,065.80+$967.26MAELIY
10$37,720,845,322$36,685,798,336.94$102,337$24,771.77+$37720.74MAELIY

AELIY vs ABBV: Complete Analysis 2026

AELIYStock

Anadolu Hayat Emeklilik Anonim Sirketi provides individual and group private pension and life insurance products in Turkey. It offers private pension products, including individual, non-sponsored group, employer-sponsored, and income drawdown plans; auto-enrolment plans; and life insurance products, such as savings and endowment, annuities, and term life. The company also provides personal and group accident insurance products; and reinsurance services. It serves customers through direct sales force, bank branches that serve as agencies, private agencies network, and alternative distribution channels. The company was formerly known as Anadolu Hayat Sigorta A.S. and changed its name to Anadolu Hayat Emeklilik Anonim Sirketi in 2003. The company was founded in 1990 and is headquartered in Istanbul, Turkey. Anadolu Hayat Emeklilik Anonim Sirketi is a subsidiary of Türkiye Is Bankasi A.S.

Full AELIY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AELIY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AELIY vs SCHDAELIY vs JEPIAELIY vs OAELIY vs KOAELIY vs MAINAELIY vs JNJAELIY vs MRKAELIY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.